In a world where the traditional way of conducting business has been disrupted for about eight months and counting, no one would have faulted the biopharmaceutical sector if its operations had been placed in a slow-down mode until the COVID-19 pandemic “all clear” had been sounded. Yet, despite the restrictions faced, companies have adapted quickly to the prevailing environment.